Interference Observed News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Interference Observed. Real-time updates on events, politics, business and more.

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

June 2, 2022

Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis

United States Paula Schwartz Edna Kaplan Jessica Breu Andreas Muehler Daniel Vitt

Source: finanznachrichten.de

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

June 2, 2022

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...

United States Paula Schwartz Edna Kaplan Jessica Breu Andreas Muehler Daniel Vitt

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Interference Observed News Today

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Explore More Categories